Registry of Endovascular Treatment for Vertebrobasilar Dissecting Aneurysms in China
VBDAs China
1 other identifier
observational
2,000
1 country
1
Brief Summary
The incidence of vertebrobasilar dissecting aneurysms (VBDAs) is about 1/100,000\~1.5/100,000, and it is one of the most important causes of stroke in young and middle-aged people. In recent years, with the development of medical imaging technology, the detection rate of this disease has been increasing year by year. The natural prognosis of VBDAs is complex and varied, with uncertainty: (1) it may have a benign course, and the imaging follow-up may show that the diseased vessels are repaired and improved or remain stable for a long period of time; (2) it may present with ischemic stroke caused by hemodynamic alteration or thromboembolism, which may result in severe neurological impairment; (3) it may occur as a result of rupture of aneurysms leading to subarachnoid hemorrhage, endangering the patient's life; (4) progressive enlargement of VBDAs causing occupying effects, which may be manifested as headache in mild cases, or hemiplegia of limbs and choking on drinking water in severe cases. Up to now, there is a lack of objective and uniform diagnostic and therapeutic guidelines for the natural regression of VBDAs and the benefits of surgery, and the treatment is mostly empirical, which makes it difficult to accurately determine the clinical prognosis of VBDAs and formulate appropriate treatment strategies. Therefore, against the above background, we designed the present study. This study was a multicenter, prospective, registry study. We enrolled patients with unruptured VBDAs who met the inclusion and exclusion criteria, and a multi-disciplinary team formulated the treatment modalities for the patients, which were categorized into the conservative observation group, the stent-assisted coiling group, and the flow diverter group. The aim of our study was to investigate the effects of different treatment modalities on the prognosis of patients with VBDAs, as well as to stratify the risk factors of the patients, to explore the individualized treatment modalities of the patients, and to improve the diagnosis and treatment of this clinically refractory cerebrovascular disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 2, 2024
CompletedFirst Posted
Study publicly available on registry
August 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2032
November 28, 2025
November 1, 2025
20 years
August 2, 2024
November 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Poor prognosis
Defined as an mRS score of 3-6.
6 months, 1 year, 3 years, and 5 years after treatment.
Aneurysm rupture
Severe headache developed after treatment and was confirmed by CT as subarachnoid hemorrhage associated with VBDAs.
6 months, 1 year, 3 years, and 5 years after treatment.
Secondary Outcomes (6)
Ischemic stroke
6 months, 1 year, 3 years, and 5 years after treatment.
Compression symptom
6 months, 1 year, 3 years, and 5 years after treatment.
VBDA-related death
6 months, 1 year, 3 years, and 5 years after treatment.
Improvement of neurological dysfunction
6 months, 1 year, 3 years, and 5 years after treatment.
Rate of complete occlusion of aneurysms
6 months, 1 year, 3 years, and 5 years after treatment.
- +1 more secondary outcomes
Study Arms (3)
Conservative management group
Patients with unruptured VBDAs did not receive any interventional therapy (including endovascular therapy and microsurgery).
Stent-assisted coiling group
Patients with unruptured VBDAs receive common stent and coils embolization.
Flow diverter group
Patients with unruptured VBDAs receive flow diverter treatment.
Interventions
1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies. 2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma.
Eligibility Criteria
Patients diagnosis of "unruptured vertebrobasilar dissecting aneurysm".
You may qualify if:
- Age 18-80 years old;
- Patients diagnosis of "unruptured vertebrobasilar dissecting aneurysm".
You may not qualify if:
- Patients did not undergo a cranial MRI;
- Missing critical clinical baseline;
- Missing pre-treatment imaging;
- Receiving microsurgery;
- The combination of other serious diseases during diagnosis will significantly affect the follow-up of patients;
- CT/MRI shows intracranial hemorrhage or subarachnoid hemorrhage (SWI microbleeds are ignored).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beijing Tiantan Hospitallead
- Beijing Chao Yang Hospitalcollaborator
- Peking University International Hospitalcollaborator
- The First People's Hospital of Lianyungangcollaborator
- Chinese PLA General Hospitalcollaborator
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technologycollaborator
- Yichang Central People's Hospitalcollaborator
- Taihe Hospitalcollaborator
- Liaocheng People's Hospitalcollaborator
- Binzhou People's Hospitalcollaborator
- The First Affiliated Hospital of Shanxi Medical Universitycollaborator
- Beijing Aerospace General Hospitalcollaborator
- The Central Hospital of Enshi Tujia And Miao Autonomous Prefecturecollaborator
- The Second Hospital of Hebei Medical Universitycollaborator
- Dalian Municipal Central Hospitalcollaborator
- Shijiazhuang Third Hospitalcollaborator
- Affiliated Hospital of Chengde Medical Universitycollaborator
- Xingtai People's Hospitalcollaborator
- Taian City Central Hospitalcollaborator
- Wuhan Brain Hospitalcollaborator
Study Sites (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100010, China
Related Publications (10)
Huang LT, Zhang M, Tong X. Cerebral revascularization for complex vertebrobasilar artery dissecting aneurysms. Neurosurg Rev. 2024 Apr 5;47(1):138. doi: 10.1007/s10143-024-02365-5.
PMID: 38578572BACKGROUNDAmoukhteh M, Hassankhani A, Valizadeh P, Jannatdoust P, Ghozy S, Kobeissi H, Kallmes DF. Flow diverters in the treatment of intracranial dissecting aneurysms: a systematic review and meta-analysis of safety and efficacy. J Neurointerv Surg. 2024 Sep 17;16(10):1005-1012. doi: 10.1136/jnis-2023-021117.
PMID: 38212103BACKGROUNDDmytriw AA, Alrashed A, Enriquez-Marulanda A, Medhi G, Mendes Pereira V. Unruptured Intradural Posterior Circulation Dissecting/Fusiform Aneurysms Natural History and Treatment Outcome. Interv Neuroradiol. 2023 Feb;29(1):56-62. doi: 10.1177/15910199211068673. Epub 2021 Dec 22.
PMID: 34935531BACKGROUNDNakatomi H, Kiyofuji S, Ono H, Tanaka M, Kamiyama H, Takizawa K, Imai H, Saito N, Shiokawa Y, Morita A, Flemming KD, Link MJ. Giant Fusiform and Dolichoectatic Aneurysms of the Basilar Trunk and Vertebrobasilar Junction-Clinicopathological and Surgical Outcome. Neurosurgery. 2020 Dec 15;88(1):82-95. doi: 10.1093/neuros/nyaa317.
PMID: 32745190BACKGROUNDAdeeb N, Ogilvy CS, Griessenauer CJ, Thomas AJ. Expanding the Indications for Flow Diversion: Treatment of Posterior Circulation Aneurysms. Neurosurgery. 2020 Jan 1;86(Suppl 1):S76-S84. doi: 10.1093/neuros/nyz344.
PMID: 31838535BACKGROUNDCho DY, Kim BS, Choi JH, Park YK, Shin YS. The Fate of Unruptured Intracranial Vertebrobasilar Dissecting Aneurysm with Brain Stem Compression According to Different Treatment Modalities. AJNR Am J Neuroradiol. 2019 Nov;40(11):1924-1931. doi: 10.3174/ajnr.A6252. Epub 2019 Oct 10.
PMID: 31601577BACKGROUNDFrisoli FA, Srinivasan VM, Catapano JS, Rudy RF, Nguyen CL, Jonzzon S, Korson C, Karahalios K, Lawton MT. Vertebrobasilar dissecting aneurysms: microsurgical management in 42 patients. J Neurosurg. 2021 Dec 10;137(2):393-401. doi: 10.3171/2021.9.JNS21397. Print 2022 Aug 1.
PMID: 34891141BACKGROUNDAhn SS, Kim BM, Suh SH, Kim DJ, Kim DI, Shin YS, Ha SY, Kwon YS. Spontaneous symptomatic intracranial vertebrobasilar dissection: initial and follow-up imaging findings. Radiology. 2012 Jul;264(1):196-202. doi: 10.1148/radiol.12112331. Epub 2012 May 1.
PMID: 22550310BACKGROUNDZhang Y, Tian Z, Sui B, Wang Y, Liu J, Li M, Li Y, Jiang C, Yang X. Endovascular Treatment of Spontaneous Intracranial Fusiform and Dissecting Aneurysms: Outcomes Related to Imaging Classification of 309 Cases. World Neurosurg. 2017 Feb;98:444-455. doi: 10.1016/j.wneu.2016.11.074. Epub 2016 Nov 24.
PMID: 27890754BACKGROUNDSonmez O, Brinjikji W, Murad MH, Lanzino G. Deconstructive and Reconstructive Techniques in Treatment of Vertebrobasilar Dissecting Aneurysms: A Systematic Review and Meta-Analysis. AJNR Am J Neuroradiol. 2015 Jul;36(7):1293-8. doi: 10.3174/ajnr.A4360. Epub 2015 May 7.
PMID: 25953763BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
August 2, 2024
First Posted
August 7, 2024
Study Start
January 1, 2011
Primary Completion (Estimated)
January 1, 2031
Study Completion (Estimated)
January 1, 2032
Last Updated
November 28, 2025
Record last verified: 2025-11